A failed clinical study has not closed the door on using GLP-1 drugs to treat vascular dementia. Researchers say the science ...

GLP-1 drugs like Ozempic and Wegovy have rapidly moved from niche diabetes treatments to blockbuster weight loss injections, ...

AI-driven discovery, EHR-based real-world evidence, and synthetic patient modeling are rapidly reshaping drug repurposing, reducing development timelines, expanding therapeutic applications, and ...

Viking Therapeutics advances oral and injectable VK2735 for obesity with strong cash, pipeline depth, and key 2026 catalysts.

Constitutional role of Congress: The framers gave the Congress the power to appropriate funds, to declare war and levy taxes, ...

Dietitian Live has mapped a repeatable subconscious-to-physiology pathway showing that when belief shifts, the body heals. The company uncovered a consistent, client-partnered process for rewiring ...

Doctors say the class of medications that includes Ozempic and Zepbound still offers health benefits for people with diabetes ...

Tantalizing results from small trials and anecdotes raised hopes that drugs like Ozempic could help. Despite setbacks, ...

The oral GLP-1 receptor agonist semaglutide (Rybelsus) did not slow Alzheimer's disease progression in the highly awaited EVOKE phase III trials, Novo Nordisk announced Monday. The company shared ...

In the Large-Cap Pharmaceuticals industry, Lilly, J&J and Sanofi are worth retaining as the industry shows some recovery.

Did you miss important current affairs from the past week? Here are the must-know topics you should catch up on: Rock Eagle ...